Target- |
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
[18F]BF3-BPA注射液在中国健康成年受试者中的药代动力学、生物分布和安全性的I期临床研究
[Translation] Phase I clinical study on the pharmacokinetics, biodistribution and safety of [18F]BF3-BPA injection in healthy adult subjects in China
1、评估中国健康成年受试者接受单次静脉注射[18F]BF3-BPA注射液后人体内的药代动力学特征和生物分布。
2、评估中国健康成年受试者接受单次静脉注射[18F]BF3-BPA注射液后人体的安全性。
[Translation] 1. To evaluate the pharmacokinetic characteristics and biodistribution in Chinese healthy adult subjects after receiving a single intravenous injection of [18F]BF3-BPA injection.
2. To evaluate the human safety of Chinese healthy adult subjects after receiving a single intravenous injection of [18F]BF3-BPA injection.
100 Clinical Results associated with Suzhou Yao Ming Bo Rui Biotechnology Co., Ltd.
0 Patents (Medical) associated with Suzhou Yao Ming Bo Rui Biotechnology Co., Ltd.
100 Deals associated with Suzhou Yao Ming Bo Rui Biotechnology Co., Ltd.
100 Translational Medicine associated with Suzhou Yao Ming Bo Rui Biotechnology Co., Ltd.